PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement Findings support continued development of PrimeC's multi-target approach in Alzheimer's disease June 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive

A newly identified molecule called OLE helped restore the brain’s immune cells to a more protective state in Alzheimer’s models. The treatment reduced toxic plaque buildup and improved memory, raising hopes for a new therapeutic approach.Researchers in Spain and Switzerland have identified an experimental molecule that may help restore the brain's natural defenses against Alzheimer's disease. The compound, known as OLE, appears to "reprogram" microglia, the brain's immune cells, allowing them to

Scientists at Baylor College of Medicine may have uncovered a promising new way to combat Alzheimer’s and Parkinson’s disease. Instead of trying to stop Tau and alpha-synuclein proteins from gathering into tiny droplets inside brain cells, the researchers found that tubulin—the protein that builds the cell’s internal transport network—can redirect these proteins away from forming toxic clumps and toward healthy, productive work.Scientists at Baylor College of Medicine have identified a potential

The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Zipalertinib (CLN-081) (Cullinan Oncology/Taiho Pharma), Firmonertinib (ArriVent BioPharma), Ivonescimab (SMT112) (Akeso Biopharma/Summit Therapeutics), PF-08046054 (Pfizer), Patritumab Deruxtecan (Daiichi Sankyo/AstraZeneca), Sacituzumab Tirumotecan (MK-2870) (Merck/Kelun-Biotech), SYS6010 (CSP

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes ASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations May 29, 2026 -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYS

Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patents May 27, 2026 -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance o

May 18, 2026 -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy tissue. It correlates with poor prognosis. On paper, it has every quality a drug develo

Researchers at the Marshall University Joan C. Edwards School of Medicine have uncovered new evidence that tiny particles created in the gut may contribute to inflammation and chronic diseases linked to aging. The findings provide fresh insight into the connection between gut health, metabolism, immune function, and even sleep-related biological stress. The study, published in Aging Cell, focused on gut luminal exosomes, microscopic particles that cells use to communicate by carrying proteins a

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24 weeks ELVN-001 maintained a favorable safety and tolerability profile with 141 patients enrolled and a median treatment duration of ~32 weeks EHA presentation will include updated data with additional patients

12-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201's favorable safety pro durable structural and functional benefits in patients with X-linked retinoschisis Three-year data from Phase 1/2 trial confirm durable efficacy and tolerability of ATSN-101 in patients with Leber congenital amaurosis type 1 Atsena is advancing ATSN-201 and ATSN-101 into pivotal clinical trials in 2026 May 07, 2026 -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-cha